N@N

NuPathe to Present at the Roth 23rd Annual OC Growth Stock Conference

  //health-fitness.news-articles.net/content/2011/ .. roth-23rd-annual-oc-growth-stock-conference.html
  Published in Health and Fitness on Friday, March 11th 2011 at 9:16 GMT by Market Wire

CONSHOHOCKEN, PA--(Marketwire - March 11, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the Roth 23^rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 7:30 p.m. EDT. The conference is being held at The Ritz Carlton in Laguna Niguel, CA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.

About NuPathe

NuPathe Inc. ([ www.nupathe.com ]) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, [ Zelrix ], is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.